SG10201608967WA - Cancer stem cell-targeted and drug resistant cancer therapy - Google Patents

Cancer stem cell-targeted and drug resistant cancer therapy

Info

Publication number
SG10201608967WA
SG10201608967WA SG10201608967WA SG10201608967WA SG10201608967WA SG 10201608967W A SG10201608967W A SG 10201608967WA SG 10201608967W A SG10201608967W A SG 10201608967WA SG 10201608967W A SG10201608967W A SG 10201608967WA SG 10201608967W A SG10201608967W A SG 10201608967WA
Authority
SG
Singapore
Prior art keywords
targeted
stem cell
drug resistant
cancer
cancer therapy
Prior art date
Application number
SG10201608967WA
Other languages
English (en)
Inventor
Angelika Burger
Original Assignee
Kominox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kominox Inc filed Critical Kominox Inc
Publication of SG10201608967WA publication Critical patent/SG10201608967WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/36Arsenic; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG10201608967WA 2009-09-10 2010-09-09 Cancer stem cell-targeted and drug resistant cancer therapy SG10201608967WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24118009P 2009-09-10 2009-09-10

Publications (1)

Publication Number Publication Date
SG10201608967WA true SG10201608967WA (en) 2016-12-29

Family

ID=43647965

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2012016747A SG179069A1 (en) 2009-09-10 2010-09-09 Cancer stem cell-targeted and drug resistant cancer therapy
SG10201608967WA SG10201608967WA (en) 2009-09-10 2010-09-09 Cancer stem cell-targeted and drug resistant cancer therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2012016747A SG179069A1 (en) 2009-09-10 2010-09-09 Cancer stem cell-targeted and drug resistant cancer therapy

Country Status (24)

Country Link
US (1) US20110059186A1 (ko)
EP (1) EP2475362B1 (ko)
JP (1) JP5710619B2 (ko)
KR (2) KR20120061908A (ko)
CN (2) CN102753164A (ko)
AR (1) AR079000A1 (ko)
AU (1) AU2010292192B2 (ko)
BR (1) BR112012008315B1 (ko)
CA (1) CA2772411C (ko)
CY (1) CY1121973T1 (ko)
DK (1) DK2475362T3 (ko)
ES (1) ES2723778T3 (ko)
HU (1) HUE043387T2 (ko)
IN (1) IN2012DN02008A (ko)
LT (1) LT2475362T (ko)
MX (1) MX2012002855A (ko)
PL (1) PL2475362T3 (ko)
PT (1) PT2475362T (ko)
RU (1) RU2568834C2 (ko)
SG (2) SG179069A1 (ko)
SI (1) SI2475362T1 (ko)
TR (1) TR201905548T4 (ko)
TW (1) TWI564012B (ko)
WO (1) WO2011031890A2 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US20120251628A1 (en) * 2011-03-30 2012-10-04 Young Joo Min Compositions and methods for treatment of cancer
KR101701235B1 (ko) 2013-09-30 2017-02-03 한국원자력의학원 Hrp-3 억제제를 포함하는 방사선 또는 약물내성 암의 치료용 약학 조성물
US20180036331A1 (en) * 2016-03-24 2018-02-08 The Board Of Regents Of The University Of Texas System Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds
CA3061905A1 (en) 2017-05-24 2018-11-29 The Regents Of The University Of California Antisense therapies for treating cancer
TWI749414B (zh) * 2019-11-29 2021-12-11 高雄醫學大學 細胞學抹片影像自動分析及診察結果自動批改方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
DE69434093T2 (de) * 1994-02-18 2006-03-09 Tamara Vasilievna Vorobieva Substanz mit immunonodulierender wirkung und zur verringerung der disfunktion des gewebezellenregelungssystems
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
DE69842094D1 (de) * 1997-10-15 2011-02-17 Polarx Biopharmaceuticals Inc Zusammensetzungen und Verfahren zur Behandlung primärer und metastatischer Erkrankungen mithilfe Arsentrioxid
ID25622A (id) * 1997-11-10 2000-10-19 Sloan Kettering Inst Cancer Proses untuk memproduksi formulasi arsenat trioksida dan metoda untuk mengobati kanker dengan menggunakan arsenat trioksida atau melarsoprol
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
US6262070B1 (en) * 1998-11-04 2001-07-17 Darwin Discovery Ltd. Heterocyclic compounds and their therapeutic use
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
MXPA04009898A (es) * 2002-04-10 2005-06-20 Korea Microbiological Lab Ltd Composicion farmaceutica que comprende arsenita para el tratamiento de tumores malignos.
WO2006104292A1 (en) * 2005-03-31 2006-10-05 Komipharm International Co., Ltd. Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US20060292243A1 (en) * 2005-06-24 2006-12-28 Shao-Chi Hsin Arsenic compounds for the treatment of the arsenic-sensitive blast-cell related diseases
US8945505B2 (en) * 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20080279961A1 (en) * 2007-05-11 2008-11-13 Burger Angelika M Telomere targeting agents as stem cells directed treatments
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
MX2012002922A (es) * 2009-09-18 2012-09-07 Kominox Inc Metodos para tratar tumores del cerebro.

Also Published As

Publication number Publication date
TR201905548T4 (tr) 2019-05-21
BR112012008315B1 (pt) 2021-08-03
IN2012DN02008A (ko) 2015-07-24
PL2475362T3 (pl) 2019-09-30
TWI564012B (zh) 2017-01-01
BR112012008315A2 (pt) 2016-09-13
ES2723778T3 (es) 2019-09-02
KR101721009B1 (ko) 2017-03-29
SI2475362T1 (sl) 2019-08-30
EP2475362A2 (en) 2012-07-18
LT2475362T (lt) 2019-06-10
WO2011031890A2 (en) 2011-03-17
DK2475362T3 (da) 2019-06-03
AU2010292192B2 (en) 2015-04-02
TW201114430A (en) 2011-05-01
WO2011031890A4 (en) 2011-10-13
CN102753164A (zh) 2012-10-24
KR20120061908A (ko) 2012-06-13
MX2012002855A (es) 2012-07-20
CA2772411C (en) 2017-08-22
KR20150038702A (ko) 2015-04-08
EP2475362B1 (en) 2019-03-27
SG179069A1 (en) 2012-04-27
WO2011031890A3 (en) 2011-08-25
HUE043387T2 (hu) 2019-08-28
CN107412771A (zh) 2017-12-01
CY1121973T1 (el) 2020-10-14
EP2475362A4 (en) 2013-03-27
JP5710619B2 (ja) 2015-04-30
CA2772411A1 (en) 2011-03-17
RU2012108144A (ru) 2013-10-20
AR079000A1 (es) 2011-12-21
US20110059186A1 (en) 2011-03-10
JP2013504587A (ja) 2013-02-07
PT2475362T (pt) 2019-05-27
AU2010292192A1 (en) 2012-03-29
RU2568834C2 (ru) 2015-11-20

Similar Documents

Publication Publication Date Title
EP2740795A4 (en) MEDICAMENT COMPOSITION FOR TREATMENT AND / OR PREVENTION OF CANCER
EP2740798A4 (en) DRUG COMPOSITION FOR CANCER TREATMENT AND / OR PREBUILDING
HK1201724A1 (en) Cancer stem cell-targeted cancer therapy
IL219073A (en) A drug combination for cancer treatment
HK1175476A1 (en) Cancer treatment
PT2582728T (pt) Conjugados fármaco-anticorpo humano contra fator tecidual
EP2531251A4 (en) ADMINISTRATION OF LOCAL THERAPY AND LOCAL ORGAN PROTECTION
EP2606349A4 (en) AGENTS FOR CANCER DIAGNOSIS AND CANCER THERAPY
ZA201300685B (en) Anticancer derivatives,preparation thereof and therapeutic use thereof
GB0922085D0 (en) Cancer diagnosis and treatment
EP2603222A4 (en) COMBINATIVE CANCER TREATMENT
IL219888A0 (en) Pyridine-pyridinone derivatives, preparation and therapeutic use thereof
ZA201201287B (en) Therapeutic aryl-amido-aryl compounds and their use
GB0918392D0 (en) Diagnostic and therapeutic methods
SG10201608967WA (en) Cancer stem cell-targeted and drug resistant cancer therapy
EP2585115A4 (en) ANTICANCER TREATMENT
GB0901837D0 (en) Cancer diagnosis and treatment
GB0905970D0 (en) Depsipeptides and their therapeutic use
EP2473613A4 (en) KREBSAUSHUNGERUNGSTHERAPIE
SI2421864T1 (sl) 1-pirazolo(4,3-c)izokinolinski derivati, njihova priprava in njihova terapevtska uporaba
GB0907973D0 (en) Combination therapy
GB0913603D0 (en) Cancer therapy
GB0921102D0 (en) Cancer Therapy
GB0907098D0 (en) Cancer treatment and diagnosis
GB0920267D0 (en) Drug combination and its use in therapy